

Box SA

Please type a plus sign(+) inside this box →

+

# UTILITY PATENT APPLICATION TRANSMITTAL

Attny Docket No. **PF482** Total Pages: **79**First Named Inventor or Application Identifier **Paul A. Moore**Date **July 21, 1999**

Only for new nonprovisional applications under 37 CFR 1.53(b)

## APPLICATION ELEMENTS

MPEP chapter 600 concerning utility patent application contents.

Assistant Commissioner for Patents

Address to: Box Patent Application  
Washington, D.C. 20231

1. ☒ Fee Transmittal Form
2. ☒ Specification [total pgs. **54**  
(preferred arrangement set forth below)
  - Descriptive title of the Invention
  - Cross References to Related Applications
  - Statement Regarding Fed Sponsored R&D
  - Reference to Microfiche Appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
3. ☒ Drawing(s) **4** Total Sheets **7**
4. ☒ Oath or Declaration Total pages **2**
  - a. ☐ Newly executed (original or copy)
  - b. ☐ Copy from a prior application (1.63(d))  
(for con/div with Box 17 completed)
    - i. ☐ Deletion of Inventors  
(signed statement attached deleting inventor(s) named in prior app.)

6. ☐ Microfiche Computer Program (appendix)
7. Nucleotide and/or Amino Acid Sequence  
Submission (if applicable, all necessary)
  - a. ☒ Computer Readable Copy
  - b. ☒ Paper Copy (identical to computer copy) [16]
  - c. ☒ Statement verifying identity of above copies

## Accompanying Application Parts

8. ☐ Assignment Papers (cover and document(s))
9. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attny
10. ☐ English Translation Document
11. ☐ Information Disclosure Statement/PTO-1449  
☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)  
(should be specifically itemized)
14. ☐ Small Entity Statement(s)  
☐ Statement filed in prior application, status still proper and desired
15. ☐ Certified copy of priority document(s)
16. ☒ Other:  
- Copy of ATCC Deposit receipt (one)

5. ☐ Incorporation by Reference (with Box 4b)  
 The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

7. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

☐ Continuation ☐ Divisional ☐ Continuation-in-Part (CIP) of prior application No.:

## 18. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label or ☒ Correspondence address below

Name **A. Anders Brookes, Esq., Attorney for Applicants**  
**Human Genome Sciences, Inc.**

Address **9410 Key West Avenue**City **Rockville**State **MD**Country **US**

Telephone

**301-309-8504**Zip Code **20850**

Fax

**301-309-8439**Reg. No. **36,373**

Signature

Date

AAB/mbp

1c542 U.S. PTO

09/350567

07/21/99

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Moore et al.

Application Serial No.: Unassigned

Art Unit: Unassigned

Filed: Herewith

Examiner: Unassigned

For: **Keratinocyte Derived Interferon**

Attorney Docket No.: **PF482**

**PATENT APPLICATION FEE VALUE**

Assistant Commissioner for Patents  
Box PATENT APPLICATION  
Washington, D.C. 20231

1c542 U.S. PTO  
09/358587  
07/21/99

Sir:

Transmitted herewith for filing under 37 C.F.R. §1.53 is the following patent application:

Applicants: Paul A. Moore  
David W. Lafeur  
Steven M. Ruben

Executed on: Unexecuted  
Unexecuted  
Unexecuted

Title of Invention: **Keratinocyte Derived Interferon**

Including: Specification (49 pgs); 20 Claims (4 pgs); Abstract (1 pg);  
4 Figures (7 sheets)

The filing fee the subject application being filed concurrently herewith has been calculated as follows:


TYPE	NO. FILE	LESS	EXTRA	EXTRA RATE	FEE
Total Claims	20	-20	0	\$18.00 each	0.00
Independent	7	-3	4	\$78.00 each	\$312.00
Minimum Fee					\$760.00
Multiple Dependency Fee if applicable (\$260.00)					
<b>Total Filing Fee</b>					<b>\$1072.00</b>

This application claims benefit of 35 U.S.C. section 119(e) based on copending U.S. Provisional Application Serial No. 60/093,643, filed July 21, 1998.

Please charge the required fee to Deposit Account No. 08-3425. In addition, the Commissioner is hereby authorized to charge payment for any additional filing fees required under 37 C.F.R. 1.16 or credit any overpayment to Deposit Account No. 08-3425. A duplicate of this paper is attached.

Respectfully submitted,

Date: 7/21/99



A. Anders Brookes (Reg. No. 36,373)  
Attorney for Applicants

Enclosure  
AAB/mbp

**Human Genome Sciences, Inc.**  
9410 Key West Avenue  
Rockville, MD 20850  
(301) 610-5761 (telephone)

# ATCC

10801 University Blvd • Manassas, VA 20110-2209 • Telephone: 703-365-2700 • FAX: 703-

## BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE

### INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT ISSUED PURSUANT TO RULE 7.3  
AND VIABILITY STATEMENT ISSUED PURSUANT TO RULE 10.2



To: (Name and Address of Depositor or Attorney)

Human Genome Sciences, Inc.  
Attn: James H. Davis  
9410 Key West Avenue  
Rockville, MD 20850

Deposited on Behalf of: Human Genome Sciences, Inc.

Identification Reference by Depositor:

ATCC Designation

DNA Plasmid PS-100 (Ref. PS-100)	203499
DNA Plasmid HKAPI15 (Ref. PF483)	203500
DNA Plasmid HOEDH76 (Ref. PF487)	203501
DNA Plasmid HB MVC21 (Ref. PF487)	203502
DNA Plasmid HWFBG79 (Ref. PF487)	203503

The deposits were accompanied by: \_\_\_ a scientific description \_ a proposed taxonomic description indicated above. The deposits were received December 1, 1998 by this International Depository Authority and have been accepted.

AT YOUR REQUEST: ☒ We will inform you of requests for the strains for 30 years.

The strains will be made available if a patent office signatory to the Budapest Treaty certifies one's right to receive, or if a U.S. Patent is issued citing the strains, and ATCC is instructed by the United States Patent & Trademark Office or the depositor to release said strains.

If the cultures should die or be destroyed during the effective term of the deposit, it shall be your responsibility to replace them with living cultures of the same.

The strains will be maintained for a period of at least 30 years from date of deposit, or five years after the most recent request for a sample, whichever is longer. The United States and many other countries are signatory to the Budapest Treaty.

The viability of the cultures cited above was tested December 10, 1998. On that date, the cultures were viable.

International Depository Authority: American Type Culture Collection, Manassas, VA 20110-2209 USA.

Signature of person having authority to represent ATCC:

Barbara M. Hailey  
Barbara M. Hailey, Administrator, Patent Depository

Date: December 11, 1998